Skip to content
Acting Auditions – Lifestyle
Author:
Silexion Therapeutics Corp
Silexion Therapeutics Receives Approval from Germany’s BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
June 23, 2026
Silexion Therapeutics to Attend BIO International Convention 2026
June 16, 2026
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
May 26, 2026
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
March 5, 2026
←
Previous Page
1
2